Evidence map›Paper›PMID 35628622›Full record

ArticleInternational journal of molecular sciences2022

In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.

Yu-Chao Lin, Wen-Yih Chen, En-Te Hwu, Wen-Pin Hu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Drugs against broad-spectrum of coronaviruses.Frontiers in immunology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Yu-Chao LinDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404333, Taiwan.
Wen-Yih ChenDepartment of Chemical and Materials Engineering, National Central University, Jhong-Li 32001, Taiwan.
En-Te HwuDepartment of Health Technology, Technical University of Denmark, 2800 Lyngby, Denmark.ORCID 0000-0002-5971-4978
Wen-Pin HuDepartment of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan.ORCID 0000-0003-1826-7689
Asia University · TWChina Medical University · TWNational Central University · TWTechnical University of Denmark · DK

Funding

China Medical University (Taiwan) and Asia University (Taiwan) ASIA-110-CMUH-04
6 · The paper itself

Abstract

Aptamers are single-stranded, short DNA or RNA oligonucleotides that can specifically bind to various target molecules. To diagnose the infected cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in time, numerous conventional methods are applied for viral detection via the amplification and quantification of DNA or antibodies specific to antigens on the virus. Herein, we generated a large number of mutated aptamer sequences, derived from a known sequence of receptor-binding domain (RBD)-1C aptamer, specific to the RBD of SARS-CoV-2 spike protein (S protein). Structural similarity, molecular docking, and molecular dynamics (MD) were utilized to screen aptamers and characterize the detailed interactions between the selected aptamers and the S protein. We identified two mutated aptamers, namely, RBD-1CM1 and RBD-1CM2, which presented better docking results against the S protein compared with the RBD-1C aptamer. Through the MD simulation, we further confirmed that the RBD-1CM1 aptamer can form the most stable complex with the S protein based on the number of hydrogen bonds formed between the two biomolecules. Based on the experimental data of quartz crystal microbalance (QCM), the RBD-1CM1 aptamer could produce larger signals in mass change and exhibit an improved binding affinity to the S protein. Therefore, the RBD-1CM1 aptamer, which was selected from 1431 mutants, was the best potential candidate for the detection of SARS-CoV-2. The RBD-1CM1 aptamer can be an alternative biological element for the development of SARS-CoV-2 diagnostic testing.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusDNA, Single-StrandedHumansMolecular Docking SimulationOligonucleotidesSARS-CoV-2DNA, Single-StrandedOligonucleotidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2aptamer–protein interactionCOVID-19DNA aptamerinfectious diseasemolecular dynamics simulationSARS-CoV-2spike protein

Identifiers

PMID35628622
PMCPMC9143595
OpenAlexW4281258745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.